EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis–Real-World Evidence up to 64 Weeks of Therapy

Patrycja Lemiesz, Julia Nowowiejska-Purpurowicz iD, Tomasz W Kaminski iD, Iwona Flisiak iD

Medical Sciences · 20.08.2026 · 14 (4) · 502

DOI: 10.3390/medsci14040502 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 20.08.2026. Verfasst von Patrycja Lemiesz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland. Hauptthemen laut MEDLINE: Psoriasis, Biological Therapy, Biological Products. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biological treatment of psoriasis has revolutionized the therapy of this disease, in most cases enabling complete remission of skin lesions.

Methods

This study aimed to analyze real-world evidence from 165 patients (mean age 38.1 ± 5.66) treated with 11 biological drugs at our Dermatology Department.

Results

Skin lesion severity, expressed by Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA), improved significantly throughout the treatment, along with the quality of life, expressed by Dermatology Life Quality Index (DLQI) (all p < 0.0001). We observed a statistically significantly higher reduction in skin lesion severity and life quality improvement with IL-23 and IL-17 inhibitors compared to TNFα inhibitors (both p < 0.0001). Secondary loss of response was observed in 26.7% of patients treated with anti-TNF agents, compared to 15.0% in the anti-IL-23 group and 8.3% in the anti-IL-17 group (χ2 test, p = 0.0683). Patients who had been treated in the past with biologics had significantly higher PASI and BSA at week 16 of therapy compared to those who were bio-naïve. A positive correlation was demonstrated between PASI at 16 weeks and BMI (R = 0.15; p = 0.0396). There was no correlation between the duration of psoriasis, sex, or age of patients when introducing biologics and PASI at any of the timepoints (p > 0.05). The most frequent side effects were infections, occurring mainly in patients on anti-TNFα agents and bimekizumab.

Conclusions

IL-17 and IL-23 inhibitors demonstrated superior efficacy compared to TNFα inhibitors, with higher rates of complete skin clearance and a lower tendency toward loss of response. The worst efficacy and the highest rate of loss of response were observed in case of adalimumab. These findings support the increasing role of IL-17 and IL-23 inhibitors as preferred therapeutic options in psoriasis. Previous biologic exposure and higher BMI seem to be associated with poorer therapeutic outcomes. Overall, biological treatment is an effective, rapid, and safe therapeutic option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological TherapyBiological ProductsHumansFemaleAdultMaleTreatment OutcomeMiddle AgedQuality of LifeSeverity of Illness IndexInterleukin-17Tumor Necrosis Factor-alphaInterleukin-23AdalimumabAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

TNFα inhibitorsadalimumabbiological drugsguselkumabpsoriasisrisankisumab

Substanzen

Interleukin-17Tumor Necrosis Factor-alphaBiological ProductsInterleukin-23AdalimumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland.
  • Department of Medicine, Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA.
  • Thrombosis and Hemostasis Program, Versiti Blood Research Institute and Blood Center of Wisconsin, Milwaukee, WI 53226, USA.

ORCID-Profile: Julia Nowowiejska-Purpurowicz, Tomasz W Kaminski, Iwona Flisiak

Zitieren

APA

Lemiesz, P., Nowowiejska-Purpurowicz, J., Kaminski, T. W., & Flisiak, I. (2026). The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis–Real-World Evidence up to 64 Weeks of Therapy. Medical Sciences, 14(4), 502. https://doi.org/10.3390/medsci14040502

Vancouver

Lemiesz P, Nowowiejska-Purpurowicz J, Kaminski TW, Flisiak I. The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis–Real-World Evidence up to 64 Weeks of Therapy. Medical Sciences. 2026;14(4):502. doi:10.3390/medsci14040502

BibTeX
@article{Lemiesz2026,
  author = {Lemiesz, Patrycja and Nowowiejska-Purpurowicz, Julia and Kaminski, Tomasz W and Flisiak, Iwona},
  title = {The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis–Real-World Evidence up to 64 Weeks of Therapy},
  journal = {Medical Sciences},
  year = {2026},
  volume = {14},
  number = {4},
  pages = {502},
  doi = {10.3390/medsci14040502}
}
Kostenlos starten →